Semler Scientific Inc
$ 20.33
-0.54%
04 Dec - close price
- Market Cap 348,270,000 USD
- Current Price $ 20.33
- High / Low $ 20.89 / 20.08
- Stock P/E 5.04
- Book Value 24.15
- EPS 4.56
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.16 %
- 52 Week High 81.56
- 52 Week Low 17.41
About
Semler Scientific, Inc. is an innovative healthcare company headquartered in Santa Clara, California, dedicated to the development and commercialization of proprietary solutions that empower healthcare providers in the evaluation and management of chronic conditions. By focusing on enhancing patient care and addressing the growing need for effective chronic disease management tools, Semler is strategically positioned to capitalize on significant market opportunities. The company's commitment to improving clinical outcomes not only underscores its strategic vision but also highlights its potential for growth within an evolving healthcare landscape, making it a compelling prospect for institutional investors.
Analyst Target Price
$75.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-04 | 2024-08-05 | 2024-05-07 | 2024-03-05 | 2023-11-09 | 2023-08-10 | 2023-05-10 | 2023-03-21 |
| Reported EPS | -0.2987 | -0.23 | -6.7426 | 3.4093 | 0.59 | 0.64 | 0.78 | 0.59 | 0.78 | 0.75 | 0.63 | 0.41 |
| Estimated EPS | -0.14 | -0.27 | None | 0.26 | 0.37 | 0.56 | 1.03 | 0.57 | 0.51 | 0.56 | 0.58 | 0.28 |
| Surprise | -0.1587 | 0.04 | 0 | 3.1493 | 0.22 | 0.08 | -0.25 | 0.02 | 0.27 | 0.19 | 0.05 | 0.13 |
| Surprise Percentage | -113.3571% | 14.8148% | None% | 1211.2692% | 59.4595% | 14.2857% | -24.2718% | 3.5088% | 52.9412% | 33.9286% | 8.6207% | 46.4286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2033 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SMLR
2025-10-18 16:51:00
The Rosen Law Firm is reminding investors of Semler Scientific, Inc. (NASDAQ: SMLR) who purchased securities between March 10, 2021, and April 15, 2025, about the October 28, 2025 deadline to apply to be lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Semler Scientific failed to disclose a material investigation by the U.S. Department of Justice into False Claims Act violations. Investors who suffered damages as a result of these alleged misrepresentations may be entitled to compensation.
2025-10-18 15:25:00
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has filed a class action lawsuit against Semler Scientific, Inc. on behalf of investors who purchased or acquired the company's securities between March 10, 2021, and April 15, 2025. The lawsuit alleges that Semler Scientific made materially false and misleading statements by failing to disclose a material investigation by the U.S. Department of Justice into violations of the False Claims Act. Investors have until October 26th to apply to be a lead plaintiff in the lawsuit.
2025-10-18 15:25:00
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Semler Scientific, Inc. (NASDAQ: SMLR) on behalf of investors who purchased securities between March 10, 2021, and April 15, 2025. The lawsuit alleges that Semler Scientific failed to disclose a material investigation by the U.S. Department of Justice into False Claims Act violations. Investors who suffered losses are encouraged to contact the firm before the October 28th deadline to apply for lead plaintiff status.
2025-10-18 14:00:00
Pomerantz LLP has filed a class action lawsuit against Semler Scientific, Inc. (NASDAQ: SMLR) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit stems from Semler's disclosures regarding a civil False Claims Act lawsuit by the U.S. Department of Justice and a subsequent $29.75 million settlement. Investors have until October 28, 2025, to seek appointment as lead plaintiff.
2025-10-17 21:53:40
Renae Cormier has resigned from her position as CFO of Semler Scientific, as disclosed in an SEC filing. This announcement comes amid other recent news for Semler Scientific, including a settlement for false claims allegations and a potential acquisition by Strive. The company is involved in developing and marketing products for evaluating and treating chronic diseases.
2025-10-17 20:10:00
Semler Scientific, Inc. announced that its Chief Financial Officer, Renae Cormier, resigned effective October 30, 2025. Dr. Douglas Murphy-Chutorian, the President and CEO, will assume the interim CFO role in addition to his current duties.
